Compare Hinge Health Inc. Class A Common Stock (HNGE) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs iShares MSCI China ETF — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while iShares MSCI China ETF trades at $51.62 (market cap $5.91B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and iShares MSCI China ETF for 65 Days on average.
| HNGE | MCHI | |
|---|---|---|
Market Cap | $8.48B | $5.91B |
Volume | 879,799 | 1,759,881 |
Sector | Health | Broad Market / Factor |
52-Week High | $105.14 | $65.59 |
52-Week Low | $31.17 | $50.48 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $8.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
MCHI, the iShares MSCI China ETF, trades at $52.135, down 0.03% on the day with a bearish technical signal from moving averages. The ETF faces mixed sentiment amid China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support and resistance cluster tightly around $52, indicating consolidation near current levels with neutral oscillator readings.
MCHI presents a valuation opportunity trading at a significant discount to historical averages versus US indices, but risks include China's regulatory uncertainty, global trade friction, and weak domestic consumption. The upcoming Trump-Xi summit on September 24 could provide catalysts through potential trade agreements, though protectionism concerns remain elevated for Chinese equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
